NO20090250L - Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte - Google Patents
Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerteInfo
- Publication number
- NO20090250L NO20090250L NO20090250A NO20090250A NO20090250L NO 20090250 L NO20090250 L NO 20090250L NO 20090250 A NO20090250 A NO 20090250A NO 20090250 A NO20090250 A NO 20090250A NO 20090250 L NO20090250 L NO 20090250L
- Authority
- NO
- Norway
- Prior art keywords
- methylphenylsulfanyl
- piperidine
- phenyl
- treatment
- neuropathic pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
Abstract
Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin og salter derav tilveiebringes f.eks. for behandling av nevropatisk smerte.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80500906P | 2006-06-16 | 2006-06-16 | |
DKPA200600816 | 2006-06-16 | ||
DKPA200700423 | 2007-03-20 | ||
PCT/DK2007/050076 WO2007144006A1 (en) | 2006-06-16 | 2007-06-15 | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090250L true NO20090250L (no) | 2009-01-16 |
Family
ID=38434468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090250A NO20090250L (no) | 2006-06-16 | 2009-01-16 | Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte |
Country Status (15)
Country | Link |
---|---|
US (4) | US8299095B2 (no) |
EP (1) | EP2044020B1 (no) |
JP (2) | JP5318757B2 (no) |
AU (1) | AU2007260356B2 (no) |
CA (1) | CA2656057C (no) |
CY (1) | CY1111619T1 (no) |
EA (1) | EA016054B1 (no) |
HK (1) | HK1134287A1 (no) |
HR (1) | HRP20110412T1 (no) |
IL (1) | IL195310A (no) |
MA (1) | MA30576B1 (no) |
MX (1) | MX2008016008A (no) |
NO (1) | NO20090250L (no) |
PL (1) | PL2044020T3 (no) |
WO (1) | WO2007144006A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602007014372D1 (de) * | 2006-06-16 | 2011-06-16 | Lundbeck & Co As H | Kristalline formen von 4-ä2-(4-methylphenylsulfany norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen |
PL2044020T3 (pl) * | 2006-06-16 | 2011-09-30 | H Lundbeck As | Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego |
BR122020011899B1 (pt) | 2006-06-16 | 2021-05-11 | H. Lundbeck A/S | processos para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina e para a fabricação do sal de adição de ácido bromídrico correspondente |
TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物 |
TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途 |
SI2167085T1 (sl) * | 2007-06-15 | 2014-05-30 | H. Lundbeck A/S | 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs) |
TW200938194A (en) * | 2007-12-14 | 2009-09-16 | Lundbeck & Co As H | Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
UA98698C2 (en) * | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
TW201033181A (en) * | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
US8940746B2 (en) | 2009-04-24 | 2015-01-27 | H. Lundbeck A/S | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine |
JP2012525426A (ja) * | 2009-04-30 | 2012-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | うつ病を治療する方法 |
WO2011136373A1 (ja) * | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
AU2017288456A1 (en) | 2016-07-01 | 2018-12-13 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
US20200048979A1 (en) | 2018-08-13 | 2020-02-13 | Saudi Arabian Oil Company | Bottomhole assembly deployment |
KR20210035228A (ko) * | 2018-08-22 | 2021-03-31 | 바스프 코포레이션 | 개선된 NOx 환원 촉매 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1084498A (en) * | 1977-05-05 | 1980-08-26 | Alexander E. Wick | Benzylpyrimidines and process for the preparation thereof |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
KR100817378B1 (ko) * | 2000-08-10 | 2008-03-27 | 미츠비시 웰파마 가부시키가이샤 | 프롤린 유도체 및 그 의약 용도 |
CZ20033154A3 (en) * | 2001-05-22 | 2004-04-14 | Pfizer Products Inc. | Crystal forms of azithromycin |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
AU2003220558A1 (en) * | 2002-03-27 | 2004-06-03 | Smithkline Beecham Corporation | Amide compounds and methods of using the same |
US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
US20060293360A1 (en) * | 2003-04-04 | 2006-12-28 | H. Lundbeck A/S | 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
SG129449A1 (en) * | 2003-07-28 | 2007-02-26 | Janssen Pharmaceutica Nv | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators |
AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
ES2375841T3 (es) * | 2005-08-29 | 2012-03-06 | Sanofi-Aventis U.S. Llc | Nueva forma cristalina de un derivado de piridazino[4,5-b]indol. |
TW200804409A (en) * | 2005-09-13 | 2008-01-16 | Sicor Inc | Processes for the synthesis of rocuronium bromide |
PL2044020T3 (pl) * | 2006-06-16 | 2011-09-30 | H Lundbeck As | Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego |
AU2007300532A1 (en) * | 2006-09-28 | 2008-04-03 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes |
US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
TWI432194B (zh) * | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途 |
CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
UA98698C2 (en) * | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
-
2007
- 2007-06-15 PL PL07764496T patent/PL2044020T3/pl unknown
- 2007-06-15 CA CA2656057A patent/CA2656057C/en not_active Expired - Fee Related
- 2007-06-15 MX MX2008016008A patent/MX2008016008A/es active IP Right Grant
- 2007-06-15 AU AU2007260356A patent/AU2007260356B2/en not_active Ceased
- 2007-06-15 JP JP2009514643A patent/JP5318757B2/ja not_active Expired - Fee Related
- 2007-06-15 US US12/303,449 patent/US8299095B2/en not_active Expired - Fee Related
- 2007-06-15 EA EA200970019A patent/EA016054B1/ru not_active IP Right Cessation
- 2007-06-15 WO PCT/DK2007/050076 patent/WO2007144006A1/en active Application Filing
- 2007-06-15 EP EP07764496A patent/EP2044020B1/en active Active
-
2008
- 2008-11-16 IL IL195310A patent/IL195310A/en active IP Right Grant
-
2009
- 2009-01-06 MA MA31551A patent/MA30576B1/fr unknown
- 2009-01-16 NO NO20090250A patent/NO20090250L/no not_active Application Discontinuation
- 2009-12-14 HK HK09111723.2A patent/HK1134287A1/xx not_active IP Right Cessation
-
2011
- 2011-05-13 CY CY20111100454T patent/CY1111619T1/el unknown
- 2011-06-03 HR HR20110412T patent/HRP20110412T1/hr unknown
-
2012
- 2012-10-25 US US13/660,718 patent/US20130190352A1/en not_active Abandoned
-
2013
- 2013-06-10 JP JP2013122095A patent/JP5650280B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-14 US US14/542,210 patent/US9315459B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 US US15/072,608 patent/US20170037006A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5318757B2 (ja) | 2013-10-16 |
EP2044020B1 (en) | 2011-05-04 |
US20170037006A1 (en) | 2017-02-09 |
EA200970019A1 (ru) | 2009-08-28 |
EP2044020A1 (en) | 2009-04-08 |
HK1134287A1 (en) | 2010-04-23 |
JP2009539890A (ja) | 2009-11-19 |
US20130190352A1 (en) | 2013-07-25 |
IL195310A (en) | 2013-12-31 |
US20090264465A1 (en) | 2009-10-22 |
JP2013216669A (ja) | 2013-10-24 |
US9315459B2 (en) | 2016-04-19 |
PL2044020T3 (pl) | 2011-09-30 |
AU2007260356A1 (en) | 2007-12-21 |
AU2007260356B2 (en) | 2013-01-24 |
WO2007144006A1 (en) | 2007-12-21 |
HRP20110412T1 (hr) | 2011-06-30 |
US20150073018A1 (en) | 2015-03-12 |
EA016054B1 (ru) | 2012-01-30 |
US8299095B2 (en) | 2012-10-30 |
CA2656057C (en) | 2012-10-02 |
MA30576B1 (fr) | 2009-07-01 |
MX2008016008A (es) | 2009-01-16 |
CA2656057A1 (en) | 2007-12-21 |
CY1111619T1 (el) | 2015-10-07 |
JP5650280B2 (ja) | 2015-01-07 |
IL195310A0 (en) | 2009-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090250L (no) | Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte | |
CY1112345T1 (el) | Πολυμορφικη μορφη της 4-[3-(4-κυκλοπροπανιοκαρβονυλ-πιπεραζιν-1-καρβονυλ)-4-φθορο-βενζυλ]-2η-φθαλαζιν-1-ονης | |
CY1117760T1 (el) | Συνδυασμος ενωσεων μορφινανης και αντικαταθλιπτικου για την αγωγη του ψευδοπρομηκικου συναισθηματος | |
NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
CO6361988A2 (es) | Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina. | |
NO20080897L (no) | Salter av 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid | |
BRPI0817537A2 (pt) | 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona | |
MY163537A (en) | 4- [2- (4-methylphenylsulfanyl)phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression | |
NO20082112L (no) | 3-Amino-2-arylpropylazaindoler og deres anvendelse | |
BRPI0816221A2 (pt) | Forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-ol)-1h-benzimidazol-4-carbox amida | |
TNSN08461A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain. | |
HK1140949A1 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] | |
NZ586010A (en) | 4-[2-(4-Methylphenylsulfanyl)phenyl]piperidine for use in the treatment of depression associated with gastrointestinal pain such as irritable bowel syndrome | |
UA95801C2 (ru) | Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли | |
EA201000611A1 (ru) | 4,4-дизамещенные пиперидины | |
DE602008005930D1 (de) | 3-(2,2,2-trimethylhydrazinium) propionat-salze zur behandlung des myokardinfarktes | |
EP2231558A4 (en) | 3,4-SUBSTITUTED PYRROLIDIN BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER | |
NO20064410L (no) | Fremgangsmate for fremstilling av tryptaseinhibitorer | |
UA101005C2 (ru) | 4-[2-(4-метилфенилсульфанил)фенил]пиперидин для лечения депрессии совместно с синдромом раздраженного кишечника (ibs) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |